Tuesday, August 30, 2022

Diagnosis of Psoriasis in Hard-To-Treat Body Locations

Diagnosis of Psoriasis in Hard-To-Treat Body Locations

Introduction

Inflammatory pathology represented by psoriasis vulgaris is much more than a simple skin condition and is a global health problem. Psoriasis for many patients results in a marked functional, psychological and social morbidity. The concept of psoriasis severity refers to many different aspects of psoriasis, including the extent of the disease, the location of the lesions, the degree of inflammation, the ability to respond to treatment and the impact on quality of life. Thus, patients with any type of psoriasis require an assessment of the severity of the disease, the impact of the disease on physical, psychological and social condition, diagnosis of the existence of psoriatic arthritis or other comorbidities. Overall assessment of the patient, assessment of the affected body surface, nail damage, affected areas with high impact and difficult to treat, or any systemic disorder such as fever, malaise, which are common in unstable forms of psoriasis such as erythroderma or generalized pustular psoriasis [1].

Psoriasis is a chronic, multisystemic disease with many comorbidities, which is often difficult to treat, and some cases may be refractory to treatment. Total eradication of plaques is difficult to achieve, and the remission time is short. Recurrence is inevitable and is often preceded by poor adherence to topical therapy. Forms of gouttate psoriasis may resolve spontaneously or may progress to chronic plaque psoriasis. Erythrodermic psoriasis and generalized pustular psoriasis can be life-threatening if left untreated and recurrences are common [2]. The clinical form of psoriasis in plaques refers to the form of well-defined erythematoussquamous plaques, “salmon-pink” to bright red, covered with thick, multilayered, non-adherent silvery white or gray-white scales. Brocq’s methodical maneuver highlights the whitening and fragmentation of the scale, and the detachment of the last layer of scales can objectify a punctiform bleeding (Auspitz sign) due to the phenomenon of papillomatosis. The annular or arched appearance may appear through the central resolution of the plaques and the confluence of the small plaques may determine the appearance of a geographical map.

The common locations are represented by the extension areas of the limbs (knees, elbows), the lumbosacral area, the scalp or the umbilical region. Clinically form of gouttate psoriasis presents multiple, round, small lesions (0.5-1 cm in diameter) (Figures 1a-1f), particularly on the trunk and upper limbs, with rapid extension, being a common form in children and young adults. Inverted (flexural) psoriasis has erythematous plaque lesions, with fine scales, in the major genito-crural, axillary and submammary folds [3]. Healthcare professionals and patients using the term psoriasis usually refer to plaque psoriasis and unless otherwise stated. The term “difficult-to-treat areas” usually refers to the face region, flexion areas, genitals (affected in 45% of cases), scalp, palmoplantar region and are so named because psoriasis in these places can have a significant impact and can lead to functional impairment and require carefully selected topical therapy, which may be resistant to treatment [4].

biomedres-openaccess-journal-bjstr

Figure 1: Clinical aspects of psoriasis vulgaris: erythematous-squamous plaques located on the extension areas of the ulnar region (a), knee (b), forearm (c), scalp (d) and psoriatic onychopathy with leuconiquia, distal onycholysis and longitudinal ridges (e), with the appearance of “oil stains” index and middle accompanied by skin lesions on the dorsal faces of the hands (f).

The scalp is one of the most common sites for psoriasis, usually with well-defined individual erythematous-squamous plaques, which often which usually extend about 1 cm beyond the hairline and advance to the cervical, retroauricular and facial regions, accompanied by pruritus and discomfort. Scalp psoriasis does not usually induce alopecia and the most common differential diagnosis of scalp psoriasis includes seborrheic dermatitis, tinea capitis and lichen planopilaris [5]. In addition, dermatomyositis involving the scalp may have lesions similar to psoriasis [2]. Flexural or inverse psoriasis is characterized by erythematous, shiny, smooth, well-defined plaques, the scales are not clearly visible due to the characteristic moisture in the folds and common topographic areas include the axillary area, sub mammary folds, groin and intergluteal fold. Inverse psoriasis is less common than plaque psoriasis and is estimated to affect 3-36% of patients [6]. In infants, it can often occur in the diaper area, with a typical damage to the groin folds, also known as napkin psoriasis. Common differential diagnoses include bacterial or Candidiasis intertrigo, tinea cruris, contact dermatitis, fold eczema and Hailey-Hailey disease [1].

Genital psoriasis affects up to 60% of patients throughout life [7] and can have a significant impact on patients’ psycho-social function due to physical symptoms such as itching and local pain, with a negative impact on sexual health [1]. As with inverse psoriasis, the scales are discrete or absent, and painful fissures in the intergluteal fissure and intense erythema can be a diagnostic argument. Vulvar psoriasis requires differential diagnosis with atopic dermatitis, contact dermatitis, sclero-atrophic lichen, lichen planus and premalignant lesions [8]. In men, irritative balanitis, Zoon balanitis, Queyrat erythroplasia or extramammary Paget’s disease can mimic genital psoriasis [8]. When nail changes or typical erythematous-squamous lesions of psoriasis are missing elsewhere in the body, skin biopsy may be helpful in establishing a certain diagnosis. The motivation of the study is given the importance of the need to outline the epidemiological profile of psoriasis which affects the quality of life through psycho-emotional impact and hard to treat body locations.

Materials & Methods

We performed a retrospective epidemiological study of 527 hospitalized patients diagnosed with psoriasis vulgaris in the Dermatological Clinic of the Emergency County Clinical Hospital “Saint Spiridon”, Iasi in order to establish the frequency of major forms of psoriasis and describe the characteristics demographics such as gender distribution, age group and hard to treat body locations in psoriasis. The collection of information from the observation sheets complied with both the type of information collected for each patient and the time intervals at which they were obtained. Criteria for inclusion in the group of patients with inflammatory pathology included patients with main clinical and/ or histological diagnosis with psoriasis vulgaris hospitalized in the Dermatology Clinic within the County Emergency Hospital “Saint” Spiridon in Iasi, during 1.01.2016-31.12.2019 for 4 years, patients whose observation sheets or electronic files contained sufficient information to make them relevant to the study. Exclusion criteria were represented by patients whose observation sheets or electronic files did not contain sufficient information to make their inclusion in the study possible.

After applying the selection criteria, a series of 527 patients was created that met all the specified conditions. The information was collected from computer databases and patient observation sheets and included a number of variables relevant to the research. Variables analyzed in the group with psoriasis vulgaris were represented by gender (female or male), age, clinical form of psoriasis (plaque psoriasis, gouttate psoriasis, palmoplantar pustular psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, inverse psoriasis, plaque and gouttate psoriasis, pustular psoriasis, inverse and gouttate psoriasis, psoriasis vulgaris in plaques, gouttate and inverse psoriasis, pustular and inverse psoriasis vulgaris, gouttate psoriasis and pustular psoriasis). Similarly, hard to treat locations distribution such as scalp, palmoplantar area, nails, genital region, large folds, face were analyzed. Quality of life was assessed using standardized Daily Life Quality Index (DLQI) severity score through questionnaire which revealed following values: 0-1 = no effect on the patient’s quality of life; 2-5 = low effect on the patient’s quality of life; 6-10 = moderate effect on the patient’s quality of life; 11- 20 = important effect on the patient’s quality of life; 21-30 = very important effect on the patient’s quality of life.

In order to carry out retrospective studies subsequently, we coded this information in order to be able to enter it in a database with parametric and non-parametric data that we analyzed statistically. The statistical analysis of the data was performed with the software STATISTICA ver. 7.0. Depending on the needs of the statistical analysis, the data were used either in the original version or were grouped according to some classification criteria imposed by methodologies, or established according to the type and particularities of the variables included in the analyzes. We analyzed the differences between the mean values according to the grouping variables, using the t test for independent samples according to the grouping variables sex and environment of origin, appreciating as significant the differences located at a significance threshold p <0.05. The significance of the differences between the frequencies was evaluated with the help of the χ2 test, appreciating as significant the differences when the calculated value of the χ2 test will be higher than the critical value corresponding to the significance threshold p = 0.05. If percentages were compared, the significance of the differences was assessed using the Z test, assessing as significant the differences located at a significance threshold p <0.05.

The present study was carried out in accordance with the 1964 Helsinki Declaration and subsequent amendments and was approved by the Ethics Commission of the University of Medicine and Pharmacy “Grigore T. Popa” Iasi and by the Ethics Commission of the Emergency County Clinical Hospital “Saint Spiridon”, Iași, through the ethics opinion in accordance with the Research Law no. 206 of 27 May 2004 on good conduct in scientific research, technological development and innovation, as well as with the European legislation in force (European Regulation 679) on the processing of personal data. The rights to integrity and confidentiality of the subjects included in the study were respected.

Results

Frequency of Cases with Special Impairment, Depending on Age Groups

To compare the frequency of cases by age groups by sex, the Z test was used to compare the percentages of two different populations (in our case men and women), at the minimum significance threshold p <0.05. The study included a number of 527 patients diagnosed with psoriasis vulgaris, with a distribution by age groups showing 229 women and 298 men, with 49.15% of the total number of the group , respectively 288 patients with urban background. After comparing the frequency with which special impairments occurred by age groups, the following (Tables 1 & 2) significant differences were obtained:

biomedres-openaccess-journal-bjstr

Table 1: Frequency of cases with special impairment, depending on age groups.

biomedres-openaccess-journal-bjstr

Table 2: Differences of frequency of cases with special impairment, depending on age groups.

a) The frequency of scalp psoriasis was significantly higher in patients aged ≤18 years (51.61% compared to 32.73% aged 19-49 years, Z = 2.01, p = 0.02; compared to 31 , 66% aged between 50-69 years, Z = 2.22, p = 0.01; compared to 29.17% aged ≥ 70 years, Z = 2.18, p = 0.01);

b) The frequency of palmar involvement was significantly higher in patients aged 50-69 years (30.5% compared to 16.13% aged ≤18 years, Z = 1.67, p = 0.047; compared to 15.76 % aged 19- 49 years, Z = 3.43, p = 0.0003; compared to 18.06% aged ≥ 70 years, Z = 2.08, p = 0.019);

c) The frequency of plantar involvement was significantly higher in patients aged 50-69 years (30.5% compared to 16.13% aged ≤18 years, Z = 1.67, p = 0.047; compared to 15.76 % aged 19- 49 years, Z = 3.43, p = 0.0003, compared to 16.67% aged ≥ 70 years, Z = 2.32, p = 0.01);

d) The frequency of nail psoriasis was significantly higher in patients aged 50-69 years (42.08% compared to 29.7% aged 19-49 years, Z = 2.57, p = 0.005 and compared to 20 , 83% aged ≥ 70 years, Z = 3.30, p = 0.0005);

e) The frequency of facial extension was significantly higher in patients aged ≤18 years (12.9% compared to 4.24% aged 19- 49 years, Z = 1.92, p = 0.027, compared to 1.16 % aged between 19-49 years, Z = 4.02, p <0.00001 and compared to 1.39% aged ≥ 70 years, Z = 2.49, p = 0.006); it was found that the frequency in patients aged 19-49 years was significantly higher than that of patients aged 50-69 years (4.24% compared to 1.16%, Z = 2.04, p = 0.02). 3.2. The relationship between the clinical form of psoriasis and the special condition:

To see if a particular clinical form of psoriasis is significantly associated with a particular special condition, it was necessary to compare the frequencies of each special condition with all the others in each clinical form of psoriasis. In order to be able to make those comparisons, it was necessary to convert the gross frequencies of each special affectation into percentage frequencies by relating them to the total cases of each corresponding special impairment, the result of which was then multiplied by 100. The differences between the percentages were tested with Z test, being considered significant those differences that were located at a significance threshold p <0.05.

Comparison of the incidence of special conditions in patients with plaque psoriasis (Table 3, Figure 2) showed that:

a) Facial psoriasis (100% of cases) was significantly more common compared to: 73.17% in the palmar area, Z = 2.3, p = 0.01; 72.13% in plantar area, Z = 2.36, p = 0.009 and 82.29% in large folds, Z = 1.77, p = 0.038;

b) Scalp involvement (93.64% of cases) was significantly more common compared to: 73.17% in the palms, Z = 4.88, p <0.00001; 72.13% in plants, Z = 5.06, p <0.00001; 87.91% for nails, Z = 1.86, p = 0.03 and 82.29% for large folds, Z = 2.92, p = 0.0017;

c) Nail psoriasis (87.91% of cases), was significantly higher than: 73.17% in palms, Z = 3.28, p = 0.0005 and 72.13% in plants, Z = 3, 48, p = 0.00025;

d) The involvement in the area of large folds (82.29% of cases) was significantly higher than 72.13% in plants, Z = 1.76, p = 0.04.

biomedres-openaccess-journal-bjstr

Table 3: Percentage frequency of clinical forms of psoriasis and special condition.

biomedres-openaccess-journal-bjstr

Figure 2: Glucose levels behavior.

In patients with inverse psoriasis it was also observed that the frequency of cases with psoriasis of genital area was significantly higher, 38.1%, compared to 20.49% with plantar area, Z = 1.77, p = 0.038. 3.3. Comparison of the frequency of cases with DLQI scores <10, between 10-20 and higher than 20 (Tables 4 & 5): In the four age groups, the results highlighted the following significant differences:

a) The frequency of cases with DLQI scores <10, was significantly higher in patients aged 50-69 years (38.22% compared to 22.58% of those aged ≤18 years, Z = 1.71, p = 0.04 and compared to 29.09% of those aged 19-59 years, Z = 2.10, p = 0.017) and those aged ≥ 70 years (44.44% compared to 22.58% of those aged ≤18 years, Z = 1.93, p = 0.027 and compared to 29.09% of those aged 19-49 years, Z = 2.3, p = 0.01); the frequency of cases with DLQI scores between 10-20, did not differ significantly depending on the age groups;

b) The frequency of cases with DLQI scores> 20, was significantly lower in patients aged ≤18 years (6.45% compared to 30.03% of those aged 19-49 years, Z = 2.76, p = 0.0028, compared to 25.48% of those aged 50-69 years, Z = 2.36, p = 0.009, compared to 36.11% of those aged ≥ 70 years, Z = 3.10, p = 0.001); the frequency of cases with DLQI scores> 20 was significantly higher in patients aged ≥ 70 years compared to those aged 50-69 years (36.11% compared to 25.48%, Z = 1.78, p = 0.037 ).

biomedres-openaccess-journal-bjstr

Table 4: Frequency of cases after DLQI score, depending on age groups.

biomedres-openaccess-journal-bjstr

Table 5: Differences by DLQI score depending on age groups.

Discussion

Psoriasis is a major global health problem with an increased prevalence with values ranging from 0.09% [9] to 11.4% [10] with a significant impact on patients’ quality of life. Clinical examination and evaluation through several tools that quantify the quality of life, such as the Dermatology Life Quality Index (DLQI). Cutaneous involvement of the scalp, face, palms, soles, nails and mucosal involvement such as genitals can be particularly debilitating [11]. Few available research on patients with psoriasis in hard-to-treat locations were based on large study populations with psoriasis. The main objective of this study was to describe patients’ clinical and demographic characteristics, disease severity, and quality of life impacts in patients with hard-to-treat body locations of psoriasis. We investigated the prevalence of hard-to-treat body locations of psoriasis, and similarly we described patients’ clinical and demographic characteristics. In the current retrospective study, the analysis of the total number of hospitalizations (527) in relation to the distribution by sex showed that each year the percentage was higher in men, the percentage frequency differences between the sexes being due to the higher number of men (298) compared with that of women (229).

Gender differences in the characteristics of skin conditions can be influenced by complex interactive mechanisms involving the effect of anatomy, physiology, immunity, genetics, epigenetics, sex hormones, ethnic background, as well as geographical, sociocultural and environmental factors. Epidemiological data reported in the literature show that psoriasis is considered equally prevalent in both sexes [12]. However, of all the studies that reported prevalence by sex, some indicated that psoriasis is more common in men [13], but the values quoted are not statistically significant, and others indicate that psoriasis appears to be less common or more widespread among women than among men [14], so further studies and investigations are needed to differentiate genetic and behavioral factors. The age distribution of the clinical forms of psoriasis vulgaris in the group of patients analyzed showed that the frequency of gouty psoriasis associated or not with erythematoussquamous plaque lesions appeared significantly higher in patients aged 18 years or less, aspects confirmed in the literature as well [15].

Psoriasis was subclassified according to the age of onset and thus psoriasis with early onset (also called type I) can occur before the age of 40, with maximum onset at the age of 16-22. Late-onset psoriasis, also called type II psoriasis, has onset at or after the age of 40, with a maximum age of onset between 57 and 60 years [16]. Other epidemiological studies indicating that the average age in patients with pustular psoriasis is reported between 48 and 50 years [17]. Another significant difference was found in patients aged ≥ 70 years in whom the frequency of reversed psoriasis appeared significantly higher with vulgaris and pustular psoriasis (98.61% compared to 92.28% in those aged 50-69 years). There is a relationship between plaque and pustular psoriasis, as some people may have episodes of plaque psoriasis that precede or follow pustular lesions, the most common trigger factors being viral or bacterial infections or improper use of corticosteroid therapy. This higher frequency may also be due to the fact that as the population of people over the age of 65 in the world continues to grow, the incidence of older people suffering from psoriasis will also increase proportionately.

Patients with the clinical form of plaque psoriasis had as the most common special location to the scalp (93.64% of cases) compared to the palmo-plantar, nail or flexural region. Psoriasis located in areas difficult to treat has a negative impact on quality of life. Thus, studies show that up to 80% of psoriasis patients develop scalp psoriasis and up to 97% of affected individuals reported that the disease affects their daily lives [18]. The frequency of facial and scalp damage was significantly higher in patients younger than 18 years and aged 19-49 years than in patients aged 50-69 years. Scalp is one of the most common sites for psoriasis and facial damage occurs at one time in about half of those affected by psoriasis. Thus, in young, active patients, the damage to these special areas by the unsightly presence of erythematous-squamous lesions on very visible areas often causes psychosocial problems. Common chronic conditions such as psoriasis may be associated with increased psychological distress [19]. Psoriasis is associated with low selfesteem, anxiety (30%) and depressive disorders (60%) [20].

The treatment of psoriasis can promote the relief of depression both due to decreased psychodynamic problems and the production of tumor necrosis factor alpha (TNF-alpha), aspects that need to be considered during therapeutic decision-making [21]. In the presence of these multiple possible comorbidities, the optimal management of the patient with psoriasis vulgaris consists in the holistic approach and the interdisciplinary approach [22]. After comparing the frequency with which special impairments occurred by age groups, it was obtained that the frequency of palmoplantar involvement was significantly higher in patients aged 50-69 years. Although palmoplantar psoriasis is a disabling variant of psoriasis and therapeutically challenging condition its epidemiology is poorly defined [23,24]. Palmoplantar psoriasis can occur at any age. Statistically analyzed data are according to available data from a systematic review and meta-analysis [25] which included a total of 2083 patients with palmoplantar psoriasis (1072 men and 841 women) and the ages of the patients ranged from 8 to 87 years, while the mean age ranged from 37.4 years to 58.5 years. With the exception of two studies, all studies reported a clinical type of palmoplantar psoriasis with hyperkeratosis, pustular or mixed plaques, and the most common was the type of hyperkeratosis plaque [25].

Also in this age group between 50-69 years the frequency of nail damage was significantly higher than those aged 19-49 years (42.08% compared to 29.7%). Literature review shows that men and women are equally affected by nail psoriasis, and its prevalence increases with the age of the study population [26]. Results from a Danish skin cohort with a total of 4016 adults with psoriasis showed that the most frequently affected hard-to-treat area was the scalp (43.0%), followed by the face (29.9%), nails (24.5%), soles (15.6%), genitals (14.1%), and palms (13.7%) [27]. Similarly to our study results, higher prevalence was generally seen with increasing psoriasis severity and patients with involvement of certain hard-totreat areas such as hands, feet, and genitals had clinically relevant DLQI impairments. Psoriasis is no longer considered just a skin disease, but rather a chronic systemic inflammatory disease that presents a substantial risk in increasing the rate of comorbidities [28]. Nail damage is an important problem in dermatological practice, and nail psoriasis may be present alone or may be associated with other skin lesions.

The nail involvement (87.91% of cases) was significantly higher than the palmoplantar area, and the damage in the area of large folds (82.29% of cases) was significantly higher than 72.13 % of the plantar area. Nail psoriasis has been reported in 10-80% of patients with psoriasis, with nails psoriasis on the upper limbs being more often affected than those on the lower limbs. Moreover psoriasis is a common cause of disturbance of the nail morphology and may be associated with all clinical forms of disease [29]. The importance of nail psoriasis was studied, and in a survey in the Netherlands, 79% of patients reported nail involvement, 52% suffering from associated pain and 14% having major restrictions in daily life due to changes in the nail apparatus [2]. Currently, the association of an inflammation of the nail bed has a prevalence between 10-80% recorded in patients with psoriasis [2]. The anatomical connection between the last phalanx and the nail unit determines the correlation between arthropathic psoriasis and nail changes [30].

Some manifestations of psoriasis are associated with an increased risk of developing other manifestations, for example, psoriatic arthropathy in patients with psoriasis with manifestations on the scalp and nails [31]. Psoriatic arthritis is a chronic systemic inflammatory disorder characterized by joint inflammation with a prevalence of 0.05% - 0.25% of the population and 6% to 41% of patients with psoriasis [32]. Although nail psoriasis is usually investigated by clinical examination, the diagnosis of incipient form of disease is needed. Patients with nail damage appear to have an increased incidence of psoriatic arthritis [33]. In the present study, out of the 527 patients with psoriasis, 98 patients presented different clinical forms of onychopathy (18.6%), a result that falls within the range reported in the literature. In our study the frequency of cases with psoriasis of genital area was significantly higher, 38.1% in patients with flexural psoriasis compared to 20.49% with plantar area, Z = 1.77, p = 0.038. Similarly, Kelly, et al. [34] reported that psoriasis involving the genital area occurs in up to two-thirds of psoriasis patients but is often overlooked by physicians.

Furthermore, often the impact this small area of psoriasis can have on a patient is neglected. It can have a significant impact on patients’ psychosocial function due to intrusive physical symptoms such as genital itch and pain, and a detrimental impact on sexual health and impaired relationships. Analysis of the distribution of DLQI values according to age groups showed a higher quality of life impairment in patients older than 70 years.

Conclusion

Hard-to-treat areas in psoriasis are represented by the scalp, face, palms, soles, nails and genital areas. The burden of disease may be due to high frequency of hard to treat body locations such as the facial and scalp regions at early age. Inverse psoriasis has frequently genital area involvement and consequently leads to a negative impact on patiens quality of life. Author Contributions: All authors contributed to the acquisition of the data and critical revision of manuscript for important intellectual content. AIP, DTO conceived review on dermoscopy. IAH and LGS conducted the retrospective study and contributed to statistical analysis and results interpretation. LS, IAP, DV and EPA wrote and conceived the manuscripts. All authors read and approved the final version of the manuscript.

For more Articles on: https://biomedres01.blogspot.com/

Saturday, August 27, 2022

Prevalence of Macroprolactin in Hyperprolactinemic Patients Receiving Anti-Psychotics

Prevalence of Macroprolactin in Hyperprolactinemic Patients Receiving Anti-Psychotics

Introduction

Prolactin hormone is a globular protein, synthesized and secreted by lactotrophs in the anterior pituitary gland [1]. The main functions of prolactin are exerted during pregnancy, enabling breast development, milk production & lactation. Prolactin (PRL) has other biological functions as osmoregulation and immunoregulation [2]. PRL facilitates the maturation of T cells via IL-2 receptor expression, impairs B cell tolerance to self-antigens through the anti-apoptotic effect, develops antigen-presenting cells, and enhances immunoglobulin production [3]. Prolactin circulates in the blood in different forms; monomeric PRL with molecular weight 23 kDa (referred to as little PRL), and it is the immunologically and biologically active form, dimeric PRL with molecular weight 48 to 56 kDa (big PRL) which is biologically inactive, and polymeric form of PRL with a molecular weight > 100 kDa (big-big PRL) which is also called a macroprolactin (MaPRL) [4]. The predominant isoform of PRL in healthy people, and also in most individuals with hyperprolactinemia, is a monomeric molecule that amounts to more than 85% of circulating hormone. However, in some patients with hyperprolactinemia, the dominant form becomes MaPRL, which in normal conditions does not exceed 2% of total serum PRL [5].

The increase in serum Prolactin concentration (hyperprolactinemia) is caused physiologically by pregnancy, lactation, stress & pain and pathologically by a pituitary adenoma (secreting PRL), hypothyroidism, chest wall disease, hepatorenal disorders, and drug-induced (anti-dopaminergic drugs). The most common drugs that cause hyperprolactinemia are the antipsychotic medicines like risperidone, haloperidol, and olanzapine [6]. However, 29% of hyperprolactinemia has been classified as idiopathic, because the causes are unknown [7]. Anti-PRL autoantibody was found to be one of the major causes of idiopathic hyperprolactinemia [8]. In most cases, MaPRL is composed of immune complexes of PRL and anti-PRL autoantibodies, and 87% of MaPRL was PRL-IgG complex and 67% of MaPRL was autoantibody-bound PRL. Anti-PRL autoantibodybound PRL is a major form of PRL-IgG complex and PRL – IgG complex is a major form of macroprolactin [9]. It has been shown that MaPRL is biologically inactive because the large molecular size of this complex prevents its crossing through the capillary blood barrier and reaching target cells and immunoglobulin connecting with a specific epitope of PRL molecule may reduce the binding of the hormone to its receptors [10,11]. So, MaPRL has longer renal clearance resulting in its accumulation in the serum. In addition, the most available immunoassays used to measure PRL level do not distinguish MaPRL from monomeric PRL, which can lead to an incorrect diagnosis of hyperprolactinemia and unnecessary imaging study and treatment.

If MaPRL has been found to predominate in human serum, it will be called macroprolactinemia. In many studies, it is found in 10 – 45% of hyperprolactinemic patients, depending on the immunoassay used in the laboratory [12-15]. Although most of the studies reported that MaPRL is inactive, some studies reported that patients with a high concentration of MaPRL exhibit signs or symptoms of hyperprolactinemia such as galactorrhea, menstrual irregularities, or infertility, other studies reported that macroprolactinemia cannot be differentiated from hyper PRL based on clinical symptoms alone, because several of the signs and symptoms of hyperprolactinemia are non-specific, the occurrence of symptoms with macroprolactinemia may be coincidental [16-18]. It is important to identify the presence of MaPRL as the cause of hyperprolactinemia to avoid unnecessary radiological investigations and treatment with dopamine agonist medicines. Macroprolactin is found to interfere with most commercially available immunoassays used for prolactin. As a result, false high prolactin values (apparent hyperprolactinemia) are obtained, and these values depend on the assay method employed. So, the most available immunoassays used to measure PRL level do not distinguish MaPRL from monomeric PRL, which can lead to an incorrect diagnosis of hyperprolactinemia and unnecessary imaging study and treatment [19].

For detection of MaPRL, Gel filtration chromatography (GFC) is the gold standard method for quantification of the three variants of PRL, but this method is costly, time-consuming, and laborintensive, so it is not used in routine screening for MaPRL [14,20]. Laboratories generally use polyethylene glycol (PEG) precipitation to differentiate macroprolactinemia from true hyperprolactinemia. This method is simple and inexpensive and has been extensively validated against GFC. This study aims to evaluate the prevalence of MaPRL in hyperprolactinemic patients in Al Masarra hospital who are receiving antipsychotic medications by precipitating MaPRL with PEG.

Materials & Methods

Patients

The study was done on 190 samples from patients with high prolactin levels and was receiving antipsychotics either male or non-pregnant non-lactating female from outpatient clinics or in-patients’ wards of the Al Masarra hospital which is a tertiary psychiatric hospital in Sultanate of Oman from March 2020 to August 2020.

Immunoassay

The measurement of the Prolactin level was measured by the automated analyzer COBAS e411, Roche Diagnostic. By using the electrochemiluminescence immunoassay “ECLIA” based on the sandwich principle, using biotinylated monoclonal specific antibody interacted with streptavidin-coated microparticles and second antibody which is monoclonal antibody labeled with a ruthenium complex. After the application of voltage, the chemiluminescent emissions were measured. The samples were separated and stored at -70 C0 till processing.

The reference range was: 102 – 496 μIU/mL for non-pregnant women and 86 – 324 μIU/mL for men. The inter-assay coefficient of variation (CV) was 2.2% and the intra-assay CV was 2.5%.

PEG-Precipitation

Preparation of 25% solution of PEG 6000 was prepared by dissolving 25 grams of PEG 6000 in 60 ml of distilled water at room temperature and mixing with vortex, then fulfilling the volumes till 100 ml of solution. The prepared solution is stable for three months maximum period at 4CO. In a separate glass tube, an equal amount of serum sample and 25% of PEG were added. After thorough vortex mixing for a minute and stabilization for 30 minutes, the solution was centrifuged at 9500 x g for 10 minutes. The supernatant portion of the sample was separated and prolactin level was measured in it. The prolactin level in the treated sample was multiplied by two to correct for the dilution with PEG. We followed the same protocol of Ana Maia Silva et al; 2014 in preparation of PEG solution and samples [21].

Measuring Free-PRL

The free prolactin is the prolactin level which will be recovered after precipitation of MaPRL by PEG.

The macroprolactin level will be determined using the following formula:

Interpretation

• Free prolactin recovering less than 40% = significant presence of MaPRL.

• Free PRL recovering that will exceed 50% = Monomeric PRL predominance.

• Free PRL recovering between 40% - 50% = intermediate or at the grey zone [22-24].

Statistical Analysis

All data were recorded and entered in a statistical package on a compatible computer and varied. Analysis was done using an SPSS- 20th version. The results were tabulated, grouped and statistically analysed using the following tests:

1. Descriptive statistics (for quantitative data)

• Mean (X-) and standard deviation (± SD)

• Frequency with percentage (for qualitative data)

2. Student Test: A statistical test used to test for a significant of an independent variable in experiments where there are only two levels of this variable (to compare between two independent means).

3. Chi-square (X2): Was used to test the significant of the difference between the frequencies of the different observations i.e. qualitative data.

4. Spearman Correlation Test (r): was used when studying the relationship (direction and power) of quantitative variables simultaneously.

5. Logistic Regression Analysis: used to examine the extent to which a set of variables independently predicts a dependent variable.

6. P value: Used to indicate the level of significance:

• P > 0.05: Insignificant

• P < 0.05: Significant

• P < 0.01: Highly significant

• P < 0.001: Very highly significant

A. Descriptive Statistics

1. Quantitative Data: mean and standard deviation “SD” were used to measure central tendency and dispersion.

2. Qualitative Data: frequency of occurrence was calculated by number (N) and percentage %.

B. Analytical Statistics

1. Comparing between groups was done using:

 Pearson Chi square- test (X2): for qualitative data.

 Student’s T test for quantitative data of two independent samples

2. Logistic regression analysis was done.

3. The level of significance was taken at (0.05). So, p value >0.05 was insignificant and p value ≤0.05 was significant.

4. The results were presented in tables and figures.

Results

The study showed that of 190 patients the mean age was 33.2 ± 9.2 years with the age range 16 – 62 years. There were 149 females (78.4 %) and 41 males (21.6%). 169 (88.9%) were Omani and 21 (11.1%) were non-Omani. The study found that 75.8% of hyperprolactinemia patients were asymptomatic and 24.2% were symptomatic. Meanwhile, (56.6%) of patients received risperidone, (29.3%) of patients received haloperidol, (9.4%) of patients received flupentixol decanoate and (4.7%) of patients received olanzapine. We found that (10.5%) of hyperprolactinemia patient had macroprolactin predominance with recovery rate (RR) was between 25.6% - 39.8% and (3.2%) of cases were borderline with RR was between 44.3% - 50%, while (86.3%) of cases had free PRL with RR was between 55 % - 98.9%. Meanwhile, 25% of MaPRL cases were males and 75% of the case were females. There was a statistically significant difference in gender between the symptomatic and asymptomatic group as males represented (28.5%) of the studied sample in the asymptomatic group and (0.0%) in the symptomatic group while females were (71.5%) in the asymptomatic group in comparison to (100.0%) in symptomatic group (p=0.00). There was a statistically significant difference in nationality between the symptomatic and asymptomatic group as Omani patients represented (92.4%) of the studied sample in the asymptomatic group and (78.3%) in the symptomatic group while non-Omani were less (7.6%) in the asymptomatic group in comparison to (21.7%) in symptomatic group (p=0.00).

There was a statistically significant difference in interpretation of hyperprolactinemia between the symptomatic and asymptomatic group as patients with free prolactin represented (86.1%) of the studied sample in the asymptomatic group and (87.0%) in the symptomatic group while patients with macroprolactin were (13.2%) in the asymptomatic group in comparison to (2.2%) in symptomatic group and patients with borderline level were (0.7%) in the asymptomatic group in comparison to (10.9%) in symptomatic group (p=0.00). There was a statistically significant difference between total prolactin and post-PEG PRL in which the mean of total PRL was 2413.6 ± 1486.0 and the mean of post-PEG PRL was 1759.37 ± 1260.5 (p = 0.000) which was following the result of Nedjeljka Ruljancic et al 2021 [25]. There was a statistically significant difference in total Prolactin between male and female in which the mean for female (2689.7 ± 1552.8) were significantly higher than in males (1410.4 ± 443.9) (p= 0.000), Also, there was a statistically significant difference macroprolactin between male and female in which the mean for female (721.7 ± 495.3) were significantly higher in than in males (408.9 ± 290.8) (p = 0.000), which was in line with the study of Young-Min Park et al 2016 [26].

There was a statistically significant difference in the type of prolactin between the symptomatic and asymptomatic group as total prolactin mean (2208.3) of the studied sample in the asymptomatic group and (3056.1) in the symptomatic group while patients with corrected prolactin mean were (1589.2) in the asymptomatic group in comparison to (2292) in symptomatic group (t-test =0.001). Meanwhile, there was no significant difference in the mean of MaPRL between the asymptomatic and symptomatic groups in the mean of MaPRL (t-test =0.007). The treatment of samples with PEG produced a reduction in PRL level in all cases with a mean reduction of 28.3%. There was no significant difference in medications used between the symptomatic and asymptomatic group as risperidone represented (81.3%) of the studied sample in the asymptomatic group and (18.7%) in the symptomatic group while haloperidol represented (64.3%) in the asymptomatic group in comparison to (35.7%) in the symptomatic group while Flupenthixol Decanoate represented (72.2%) in the asymptomatic group in comparison to (27.8%) in symptomatic group and olanzapine represented (88.9%) in the asymptomatic group in comparison to (11.1%) (p=0.079) which was on the contrary of the study of Young-Min Park et al 2016.

The mean of total PRL & MaPRL was higher in patients who were receiving haloperidol more than the other medications. (Table 1 & Figure 1). In our study there was a positive correlation between total prolactin and macroprolactin levels (r = 0.59, p < 0.01) (Figure 2).

biomedres-openaccess-journal-bjstr

Figure 1:The mean of PRL & MaPRL in Olanzapine, Flupenthixol Decanoate, and Haloperidol & Risperidone. (The figure shows that the mean of the total prolactin level and the mean of macroprolactin levels were higher in patients receiving haloperidol that in other medicines).

biomedres-openaccess-journal-bjstr

Figure 2:Correlation between total PRL & MaPRL (The figure shows the positive correlation between the values of the prolactin level and the values of macroprolactin levels).

biomedres-openaccess-journal-bjstr

Table 1: Mean of Total PRL & MaPRL of Olanzapine, Haloperidol, and Risperidone & Flupenthixol Decanoate.

Discussion

Macroprolactin was described for the first time by Wittaker et al in 1981 when they reported a case with hyperprolactinemia without the common symptoms of amenorrhea, galactorrhea, and infertility. It was found that the high molecular weight MaPRL accounted for the majority of PRL in this patient by using GFC. It is PRL-IgG immunocomplex in which endogenous IgG molecule is directed against epitopes on N- and C-terminal restudies of monomeric PRL [27]. In the present study, treatment of the sera of patients with high prolactin with 25 % PEG 6000 was done leading to precipitation of macroprolactin and free prolactin level was measured in the supernatant. This method is the easiest and cheapest method for detecting MaPRL but it can precipitate monomeric PRL also with MaPRL leads to a reduction of post-PEG PRL values in all serum samples with a mean reduction of 28.3% in this study. In our study, we used the most common cut-off <40 % recovery rate to consider the case positive for macroprolactinemia. It has been reported that the 40% cutoff is 100% sensitive to confirm the presence of MaPRL while using a 60% cutoff does not report significantly more patients with significant macroprolactinemia [28].

In our study, 10.5% were detected with macroprolactin predominance which is consistent with studies that have been documented in the United States which found that about 10% of hyperprolactinemic patients have MaPRL as a predominant form of PRL but most of the studies conducted in Europe have shown that the predominance of MaPRL is usually above 20% [27-29]. 95 % of cases of MaPRL were asymptomatic and 5 % were complaining of amenorrhea. Although MaPRL is biologically inactive the symptoms could be co-incidence or intermittent dissociation of macroprolactin from IgG molecule could happen and causing the symptoms as suggested by Hattori N et al in 1997 [30]. Suliman AM et al also explained that although Big-Big PRL may be the predominant molecular form in MaPRL, monomeric PRL may simultaneously be found in excess. Therefore, MaPRL could be associated with monomeric hyperprolactinemia which leads to the development of symptoms of hyperprolactinemia [31]. In our study prolactin levels and macroprolactin levels were significantly higher in females than males as the previous results of Johnsen, et al. [32- 33]. The antipsychotic-induced hyperprolactinemia is related to differential D2 receptor affinity, 5-hydroxytryptamine receptor affinity, and blood-brain disposition of antipsychotics [34].

Risperidone is one of the anti-psychotics that have poor bloodbrain barrier penetration and high concentrations of risperidone exist in the pituitary [35]. In our study risperidone appeared to increase prolactin in 56.3% of patients, haloperidol was the second medicine which increased PRL in 29.5% of patients, Flupenthixol Decanoate increased PRL in 9.5% of patients and Olanzapine was the fourth medicine which increased PRL in 4.7 % of patients. In our study, there was no significant difference in medications used between the symptomatic and asymptomatic groups. The mean prolactin and macroprolactin levels were higher in patients who were receiving haloperidol than the other medicines but was no statistically significant difference between them. Beda-Maluga et al. reported that most patients with a PRL concentration higher than 100 ng/ml (2127 uIU/mL) had true hyperprolactinemia, although significant macroprolactinemia might be present in some cases [36]. The American Association of Clinical Endocrinologists recommends using a 25–150 ng/mL (532 - 3191 uIU /mL) interval to search for MaPRL, and the Endocrine Society suggests testing every asymptomatic patient for hyperprolactinemia [37]. Our study shed light on the prevalence of macroprolactin in patients receiving antipsychotics by measuring the prolactin level by COBAS e411 analyzer, we suggest in the future study increasing the number of patients and studying the prevalence of macroprolactin using different platforms other than COBAS analyzers.

Conclusion

Macroprolactin predominance in hyperprolactinemia patients receiving antipsychotics was 10.5 % which is in line with many kinds of literature. Haloperidol was associated with increased total and macroprolactin levels more than other drugs. So, we recommend investigation for macroprolactin predominance in every hyperprolactinemia patient especially the asymptomatic cases to avoid unnecessary radiological imaging and treatment.

For more Articles on: https://biomedres01.blogspot.com/

Academic Anxiety and School Burnout in Adolescents

  Academic Anxiety and School Burnout in Adolescents Introduction In 2020, the COVID-19 pandemic dramatically changed our lives, both person...